Table 2.
Clinical Characteristics of Women with Incident Breast Cancer by Rural–Urban Residence at Time of Diagnosis; Women's Health Initiative (n = 7,120), 1993–2014
| Rural–urban category | ||||
|---|---|---|---|---|
| Characteristics | Total N = 7,120 (%) | Urban N = 6,643 (%) | Large rural N = 265 (%) | Small rural N = 212 (%) |
| Approximate age (years) at diagnosis | ||||
| 50 to <60 | 995 (14) | 940 (14) | 27 (10) | 28 (13) |
| 60 to <70 | 3,089 (43) | 2,858 (43) | 134 (51) | 97 (46) |
| 70 to <80 | 2,648 (37) | 2,480 (37) | 90 (34) | 78 (37) |
| ≥80 | 388 (5) | 365 (5) | 14 (5) | 9 (4) |
| SEER stage | ||||
| In situ | 1,210 (17) | 1,122 (17) | 45 (17) | 43 (20) |
| Local | 4,178 (59) | 3,901 (59) | 156 (59) | 121 (57) |
| Regional | 1,331 (19) | 1,240 (19) | 55 (21) | 36 (17) |
| Distant | 63 (1) | 57 (1) | 1 (0) | 5 (2) |
| Morphology—grade | ||||
| 1: Well differentiated | 1,421 (20) | 1,337 (20) | 43 (16) | 41 (19) |
| 2: Moderately differentiated | 2,481 (35) | 2,304 (35) | 95 (36) | 82 (39) |
| 3: Poorly differentiated | 1,583 (22) | 1,477 (22) | 64 (24) | 42 (20) |
| 4: Anaplastic | 476 (7) | 441 (7) | 22 (8) | 13 (6) |
| Unknown/not done/missing | 1,159 (16) | 1,084 (16) | 41 (15) | 34 (16) |
| Hormone receptor status | ||||
| ER/PR+ | 3,605 (51) | 3,369 (51) | 138 (52) | 98 (46) |
| ER+/PR− | 802 (11) | 756 (11) | 20 (8) | 26 (12) |
| ER−/PR+ | 83 (1) | 77 (1) | 3 (1) | 3 (1) |
| ER/PR− | 792 (11) | 721 (11) | 37 (14) | 34 (16) |
| Borderline/unknown/missing ER and/or PR status | 1,838 (26) | 1,720 (26) | 67 (25) | 51 (24) |
| HER-2/Neu | ||||
| Positive | 693 (10) | 638 (10) | 37 (14) | 18 (8) |
| Negative | 2,919 (41) | 2,735 (41) | 97 (37) | 87 (41) |
| Borderline/unknown/missing | 3,508 (49) | 3,270 (49) | 131 (49) | 107 (50) |
ER, estrogen receptor; PR, progesterone receptor; SEER, surveillance, epidemiology, and end results.